| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 8888888 |
Internal/system code - not a standard HCPCS code |
26,326 |
8,520 |
$7.21M |
| 36415 |
Collection of venous blood by venipuncture |
8,383 |
6,670 |
$1.06M |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
762 |
719 |
$138K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
3,809 |
3,589 |
$128K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
3,926 |
3,581 |
$52K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
939 |
868 |
$51K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
3,606 |
3,069 |
$31K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
296 |
282 |
$29K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
3,413 |
2,984 |
$27K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
427 |
395 |
$25K |
| 71045 |
Radiologic examination, chest; single view |
1,202 |
1,107 |
$22K |
| 71046 |
Radiologic examination, chest; 2 views |
654 |
630 |
$21K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
1,906 |
1,650 |
$21K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
242 |
195 |
$20K |
| 81001 |
|
2,396 |
2,122 |
$18K |
| 70450 |
Computed tomography, head or brain; without contrast material |
301 |
279 |
$17K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
820 |
752 |
$15K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
104 |
50 |
$14K |
| 82962 |
|
253 |
184 |
$14K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
280 |
269 |
$14K |
| 81003 |
|
1,434 |
1,312 |
$13K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
315 |
274 |
$12K |
| U0001 |
Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel |
308 |
294 |
$9K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
2,680 |
2,236 |
$8K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
1,616 |
1,251 |
$7K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
6,094 |
4,965 |
$7K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
726 |
639 |
$6K |
| 80053 |
Comprehensive metabolic panel |
5,483 |
4,600 |
$6K |
| 87088 |
|
418 |
381 |
$5K |
| 84703 |
|
1,676 |
1,512 |
$5K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
281 |
200 |
$5K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
1,713 |
1,525 |
$4K |
| 59025 |
Fetal non-stress test |
507 |
361 |
$4K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
170 |
165 |
$4K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
277 |
248 |
$4K |
| J3490 |
Unclassified drugs |
29 |
22 |
$4K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
37 |
37 |
$4K |
| 83690 |
|
1,747 |
1,512 |
$3K |
| 99001 |
|
90 |
87 |
$3K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
50 |
49 |
$3K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
3,649 |
2,762 |
$3K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
66 |
62 |
$3K |
| 86710 |
|
54 |
54 |
$3K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,758 |
1,499 |
$3K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
1,837 |
1,233 |
$2K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
82 |
72 |
$2K |
| 87400 |
|
69 |
62 |
$2K |
| G0500 |
Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) |
91 |
78 |
$2K |
| 80050 |
General health panel |
624 |
577 |
$1K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
35 |
32 |
$1K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
897 |
803 |
$1K |
| 80143 |
|
154 |
135 |
$999.10 |
| 87081 |
|
18 |
17 |
$924.97 |
| 31720 |
|
19 |
15 |
$917.94 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
840 |
736 |
$842.16 |
| 87077 |
|
44 |
43 |
$802.28 |
| 87631 |
|
13 |
13 |
$662.66 |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
86 |
82 |
$620.20 |
| 81025 |
|
281 |
253 |
$579.28 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
520 |
439 |
$546.08 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
115 |
95 |
$428.80 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
13 |
13 |
$336.51 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
1,505 |
1,033 |
$300.00 |
| J2704 |
Injection, propofol, 10 mg |
1,847 |
1,467 |
$299.59 |
| 99152 |
|
42 |
38 |
$274.11 |
| A9270 |
Non-covered item or service |
1,688 |
366 |
$248.47 |
| 94760 |
|
567 |
408 |
$181.89 |
| 93971 |
|
13 |
13 |
$115.64 |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
28 |
12 |
$68.68 |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
26 |
24 |
$65.64 |
| 84443 |
Thyroid stimulating hormone (TSH) |
221 |
202 |
$40.00 |
| 82077 |
|
273 |
242 |
$0.00 |
| 96376 |
|
613 |
507 |
$0.00 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
781 |
477 |
$0.00 |
| 83605 |
|
159 |
135 |
$0.00 |
| 80048 |
Basic metabolic panel (calcium, ionized) |
338 |
268 |
$0.00 |
| 85379 |
|
109 |
104 |
$0.00 |
| 84484 |
|
1,082 |
847 |
$0.00 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
111 |
106 |
$0.00 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
528 |
363 |
$0.00 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
367 |
336 |
$0.00 |
| 99153 |
Mod sedat endo service >5yrs |
58 |
53 |
$0.00 |
| 80320 |
|
33 |
30 |
$0.00 |
| 86140 |
|
14 |
13 |
$0.00 |
| 88342 |
|
103 |
89 |
$0.00 |
| 83880 |
|
98 |
90 |
$0.00 |
| J2060 |
Injection, lorazepam, 2 mg |
147 |
110 |
$0.00 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
97 |
81 |
$0.00 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
163 |
160 |
$0.00 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
33 |
32 |
$0.00 |
| G0378 |
Hospital observation service, per hour |
83 |
53 |
$0.00 |
| 85730 |
|
25 |
24 |
$0.00 |
| 83735 |
|
13 |
12 |
$0.00 |
| 85652 |
|
14 |
13 |
$0.00 |
| 82607 |
|
32 |
29 |
$0.00 |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
19 |
15 |
$0.00 |
| 80329 |
|
25 |
24 |
$0.00 |
| 87503 |
|
12 |
12 |
$0.00 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
434 |
369 |
$0.00 |
| 80179 |
|
148 |
129 |
$0.00 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
634 |
476 |
$0.00 |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
34 |
28 |
$0.00 |
| 80061 |
Lipid panel |
119 |
107 |
$0.00 |
| 85610 |
|
258 |
214 |
$0.00 |
| A4649 |
Surgical supply; miscellaneous |
34 |
31 |
$0.00 |
| C1713 |
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) |
25 |
24 |
$0.00 |
| 87186 |
|
63 |
59 |
$0.00 |
| 84439 |
|
44 |
41 |
$0.00 |
| 87420 |
|
31 |
29 |
$0.00 |